Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Adenocarcinoma, Clear Cell
/ drug therapy
Adult
Aged
Angiogenesis Inhibitors
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bevacizumab
/ therapeutic use
Carboplatin
/ therapeutic use
Confidence Intervals
Cystadenocarcinoma, Serous
/ drug therapy
Deoxycytidine
/ analogs & derivatives
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Odds Ratio
Ovarian Neoplasms
/ drug therapy
Paclitaxel
/ therapeutic use
Progression-Free Survival
Retrospective Studies
Gemcitabine
Bevacizumab
Clear cell carcinoma
Growth modulation index
Recurrent ovarian cancer
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
25
05
2020
accepted:
27
06
2020
pubmed:
12
7
2020
medline:
15
9
2021
entrez:
12
7
2020
Statut:
ppublish
Résumé
Treatment of recurrent ovarian carcinoma is a challenge, particularly for the clear cell (CCC) subtype. However, there is a preclinical rationale that these patients could achieve a benefit from antiangiogenic therapy. To assess this hypothesis, we used the growth modulation index (GMI), which represents an intrapatient comparison of two successive progression-free survival (PFS). We conducted a retrospective real-world study performed on 34 patients with recurrent ovarian cancer, treated with bevacizumab-containing regimens from January 2009 to December 2017. The primary endpoint was GMI. An established cut-off > 1.33 was defined as a sign of drug activity. 73.5% of patients had high-grade serous ovarian carcinoma (HGSOC), and 17.7% had CCC; 70.6% of patients received carboplatin/gemcitabine/bevacizumab, and 29.4% received weekly paclitaxel/bevacizumab. According to histological subtype, the overall response rate and median PFS were 52% and 14 months for HGSOC and 83.3% and 20 months for CCC, respectively. The overall population median GMI was 0.99; it was 0.95 and 2.36 for HGSOC and CCC, respectively. CCC subtype was significantly correlated with GMI > 1.33 (odds ratio 41.67; 95% confidence interval 3.6-486.94; p = .03). Adding bevacizumab to chemotherapy in recurrent CCC is associated with a remarkable benefit in this cohort. The efficacy of antiangiogenic drugs in CCC warrants further prospective evaluation.
Identifiants
pubmed: 32651885
doi: 10.1007/s12094-020-02446-z
pii: 10.1007/s12094-020-02446-z
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Antineoplastic Agents, Immunological
0
Deoxycytidine
0W860991D6
Bevacizumab
2S9ZZM9Q9V
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Gemcitabine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
536-542Références
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.
doi: 10.1056/NEJMoa1104390
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.
doi: 10.1056/NEJMoa1103799
Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139(1):10–6.
doi: 10.1016/j.ygyno.2015.08.004
Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–91.
doi: 10.1016/S1470-2045(17)30279-6
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8.
doi: 10.1200/JCO.2013.51.4489
Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(24):3621–7.
doi: 10.1200/JCO.2006.10.2517
Kajiyama H, Suzuki S, Yoshikawa N, et al. Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary. Int J Gynecol Cancer. 2019;29(5):910–5.
doi: 10.1136/ijgc-2018-000142
Hogen L, Vicus D, Ferguson SE, et al. Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma. Int J Gynecol Cancer. 2019;29(7):1164–9.
doi: 10.1136/ijgc-2019-000287
Lee S, Garner EI, Welch WR, et al. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol. 2007;106(2):311–7.
doi: 10.1016/j.ygyno.2007.03.041
Mabuchi S, Sugiyama T, Kimura T. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol. 2016;27(3):e31.
doi: 10.3802/jgo.2016.27.e31
Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs—twenty-first richard and hinda rosenthal foundation award lecture. Clin Cancer Res. 1998;4(5):1079–86.
Penel N, Demetri GD, Blay JY, et al. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol. 2013;24(2):537–42.
doi: 10.1093/annonc/mds470
Oza AM, Cook AD, Pfisterer J, et al. ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36.
doi: 10.1016/S1470-2045(15)00086-8
Lee JY, Park JY, Park SY, et al. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): a Korean Gynecologic Oncology Group study (KGOG 3041). Gynecol Oncol. 2019;152(1):61–7.
doi: 10.1016/j.ygyno.2018.10.031
Crotzer DR, Sun CC, Coleman RL, et al. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007;105(2):404–8.
doi: 10.1016/j.ygyno.2006.12.024
Oliver KE, Brady WE, Birrer M, et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017;147(2):243–9.
doi: 10.1016/j.ygyno.2017.08.004
Rocha AL, Reis FM, Taylor RN. Angiogenesis and endometriosis. Obstet Gynecol Int. 2013;2013:859619.
doi: 10.1155/2013/859619
Laschke MW, Elitzsch A, Vollmar B, et al. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod. 2006;21(1):262–8.
doi: 10.1093/humrep/dei308
Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11(18):6422–30.
doi: 10.1158/1078-0432.CCR-05-0508
Chandler RL, Damrauer JS, Raab JR, et al. Coexistent ARID1A–PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat Commun. 2015;6:6118.
doi: 10.1038/ncomms7118
Anglesio MS, George J, Kulbe H, et al. IL6–STAT3–HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011;17(8):2538–48.
doi: 10.1158/1078-0432.CCR-10-3314
Mabucci S, Kawase C, Altomare DA, et al. VEGF is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther. 2010;9(8):2411–22.
doi: 10.1158/1535-7163.MCT-10-0169
Ji JX, Wang YK, Cochrane DR, Huntsman DG. Clear cell carcinomas of the ovary and kidney: clarity through genomics. J Pathol. 2018;244(5):550–64.
doi: 10.1002/path.5037
Fogli S, Porta C, Del Re M, et al. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 2020;84:101966.
doi: 10.1016/j.ctrv.2020.101966
Ishikura N, Yorozu K, Kurasawa M, et al. Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model. Oncol Rep. 2019;42(3):1057–65.
pubmed: 31322247
pmcid: 6667843
Chan JK, Brady W, Monk BJ, et al. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018;150(2):247–52.
doi: 10.1016/j.ygyno.2018.05.029